NCT04663386
Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway
Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway; A Retrospective, Observational Study to Evaluate the Impact on Disease Control in Patients With Asthma and/or Chronic Obstructive Pulmonary Disease (COPD)
Orion Corporation, Orion Pharma·ClinicalTrials.gov·drugTerminated
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Asthma,COPD
- Drug/Device/Intervention
- Budesonide-Formoterol
- Study type
- Observational
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Orion Corporation, Orion Pharma
- Location
- Hønefoss, Norway
Timeline & enrollment
- Phase
- N/A
- Start date
- Dec 10, 2020
- End date
- Sep 14, 2021
- Enrollment
- 29 participants
Primary outcome
Disease control
Summary
This is a retrospective, multicentre, non-interventional, observational study in patients
 with asthma and/or COPD who are treated with budesonide-formoterol.
ICD-10 classifications
AsthmaAsthma, unspecifiedNonallergic asthmaMixed asthmaOther chronic obstructive pulmonary disease
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT04663386
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT04663386 through Pure Global AI's free database. This phase not specified trial is sponsored by Orion Corporation, Orion Pharma and is currently Terminated. The study focuses on Asthma,COPD. Target enrollment is 29 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.